Linear growth and bone metabolism in pediatric patients with inflammatory bowel disease

被引:10
|
作者
Lima Simoes Ferreir, Paloma Velez de Andrade [1 ,2 ]
Cavalcanti, Andre de Souza [3 ]
Pontes da Silva, Giselia Alves [1 ,3 ]
机构
[1] Univ Fed Pernambuco UFPE, PPGSCA, Recife, PE, Brazil
[2] Inst Med Integral Prof Fernando Figueira IMIP, Recife, PE, Brazil
[3] Univ Fed Pernambuco UFPE, Dept Maternoinfantil, Recife, PE, Brazil
关键词
Inflammatory bowel disease; Growth failure; Low bone mineraldensity; WEIGHT HEIGHT VELOCITY; BODY-COMPOSITION; MINERAL DENSITY; TRANSGENIC MICE; CHILDREN; GLUCOCORTICOIDS; OSTEOIMMUNOLOGY; RETARDATION; IMPROVEMENT; NUTRITION;
D O I
10.1016/j.jped.2018.11.002
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: To review the pathophysiology and evaluation methods of linear growth and bone mineral density in children and adolescents diagnosed with inflammatory bowel disease. Source of data: Narrative review carried out in the PubMed and Scopus databases through an active search of the terms: inflammatory bowel disease, growth, failure to thrive, bone health, bone mineral density, and children and adolescents, related to the last ten years, searching in the title, abstract, or keyword fields. Synthesis of findings: Inflammatory bowel diseases of childhood onset may present as part of the clinical picture of delayed linear growth in addition to low bone mineral density. The presence of a chronic inflammatory process with elevated serum levels of inflammatory cytokines negatively interferes with the growth rate and bone metabolism regulation, in addition to increasing energy expenditure, compromising nutrient absorption, and favoring intestinal protein losses. Another important factor is the chronic use of glucocorticoids, which decreases the secretion of growth hormone and the gonadotrophin pulses, causing pubertal and growth spurt delay. In addition to these effects, they inhibit the replication of osteoblastic lineage cells and stimulate osteoclastogenesis. Conclusion: Insufficient growth and low bone mineral density in pediatric patients with inflammatory bowel disease are complex problems that result from multiple factors including chronic inflammation, malnutrition, decreased physical activity, late puberty, genetic susceptibility, and immunosuppressive therapies, such as glucocorticoids. (C) 2018 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.
引用
收藏
页码:S59 / S65
页数:7
相关论文
共 50 条
  • [41] Clinical relevance of changes in bone metabolism in inflammatory bowel disease
    Miheller, Pal
    Lorinczy, Katalin
    Lakatos, Peter Laszlo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (44) : 5536 - 5542
  • [42] Ultrasonographic imaging of inflammatory bowel disease in pediatric patients
    Chiorean, Liliana
    Schreiber-Dietrich, Dagmar
    Braden, Barbara
    Cui, Xin-Wu
    Buchhorn, Reiner
    Chang, Jian-Min
    Dietrich, Christoph F.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (17) : 5231 - 5241
  • [43] Eosinophilic esophagitis in pediatric patients with inflammatory bowel disease
    Doherty, T.
    Dohil, R.
    Bastian, J.
    Newbury, R.
    Aceves, S.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 100 (01) : A70 - A70
  • [44] Disaccharidase Deficiency in Pediatric Patients with Inflammatory Bowel Disease
    Friesen, Chance S.
    San Pablo, William
    Bass, Julie
    Garg, Uttam
    Colombo, Jennifer M.
    GASTROINTESTINAL DISORDERS, 2022, 4 (01): : 1 - 7
  • [45] Vedolizumab Use in Pediatric Patients With Inflammatory Bowel Disease
    Singh, Namita
    Patel, Minesh
    Rabizadeh, Shervin
    Dubinsky, Marla
    GASTROENTEROLOGY, 2015, 148 (04) : S72 - S72
  • [46] Use of rifaximin in pediatric patients with inflammatory bowel disease
    Muniyappa, Pramodha
    Gulati, Reema
    Vera, Hupertz
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S551 - S551
  • [47] GROWTH AFTER MENARCHE IN PEDIATRIC-PATIENTS WITH CHRONIC INFLAMMATORY BOWEL-DISEASE
    KIRSCHNER, BS
    UEBLER, N
    SUTTON, MM
    GASTROENTEROLOGY, 1993, 104 (04) : A629 - A629
  • [48] Dermatologic manifestations in pediatric patients with inflammatory bowel disease
    Afarideh, Mohsen
    Bartoletta, Katherine
    Tollefson, Megha M.
    PEDIATRIC DERMATOLOGY, 2024, 41 (02) : 234 - 242
  • [49] Use of infliximab in pediatric patients with inflammatory bowel disease
    Serrano, MS
    Schmidt-Sommerfeld, E
    Kilbaugh, TJ
    Brown, RF
    Udall, JN
    Mannick, EE
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (7-8) : 823 - 828
  • [50] Methotrexate therapy for pediatric patients with inflammatory bowel disease
    Kirschner, BS
    INFLAMMATORY BOWEL DISEASES, 1998, 4 (02) : 121 - 123